BOSTON, Jan. 3, 2023 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”) AVEO, a commercial-stage oncology biopharmaceutical company dedicated to providing medicines that help cancer patients live better lives, reminds all AVEO shareholders to “FOR” the Approve the Agreement and Proposal of Merger between LG Chem, Ltd. (“LG Chem”), a subsidiary of LG Chem and AVEO (the “Merger Agreement”). Subject to the terms of the merger agreement, including obtaining necessary AVEO stockholder approvals at the special meeting, LG Chem will acquire AVEO for merger consideration of $15.00 per share in cash. The special meeting is scheduled for January 5, 2023 at 10:00 a.m. Eastern Time.

As previously announced, AVEO’s board of directors is unanimously recommending that stockholders vote in favor of the merger agreement and each of the other proposals to be voted on at the special meeting. The merger consideration represents a compelling 43% premium to AVEO’s closing price on October 17, 2022.

Your vote matters, no matter how few or how many shares you own.
AVEO is also pleased to announce that leading proxy advisory firms Institutional Shareholder Services Inc. and Glass, Lewis & Co. both recommend that AVEO shareholders vote “FOR” to approve the merger agreement and each of the other proposals, to be voted on at the special session.

How to vote
AVEO shareholders of record as of the close of business on November 18, 2022 (the “Record Date”) who have not yet voted are urged to submit their votes by telephone at 1-866-230-6355 or web at www.proxypush.com/AVEO Following the instructions on their proxy or voting instruction forms. Shareholders must cast their vote by proxy no later than 9:59 a.m. Eastern Time on January 5, 2023, the date of the special meeting.

Shareholders who have not received their voting material by the deadline or who…